Company intelligence / Profile preview
NeRRe Therapeutics
Stevenage, Hertfordshire, United Kingdomnerretherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed Phase 2b study (VOLCANO-2) in patients with refractory or unexplained chronic cough, demonstrating that orvepitant 30 mg once daily resulted in rapid and sustained improvements in several clinically relevant patient reported outcome assessments of cough burden. Currently evaluating orvepitant for chronic cough in patients with IPF.
- Therapeutic areas
- Pulmonology
- Modalities
- Small molecules (neurokinin receptor antagonists)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
GlaxoSmithKline (GSK) - original source of assets
Beyond the preview
Go deeper on NeRRe Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeRRe Therapeutics.